Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE

• Published in: Lupus science & medicine Vol. 9; no. 1; p. e000704
• Main Authors: Kamen, Diane L, Wallace, Caroline, Li, Zihai, Wyatt, Megan, Paulos, Crystal, Wei, Chungwen, Wang, Hongjun, Wolf, Bethany J, Nietert, Paul J, Gilkeson, Gary
• Format: Journal Article
• Language: English
• Published: England Lupus Foundation of America 01.07.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: Autoimmunity; B-Lymphocytes; Bone marrow; Clinical Trials and Drug Discovery; Disease; Female; Humans; Immune system; Immunology; Lupus; Lupus Erythematosus, Systemic; Lupus Erythematosus, Systemic - drug therapy; Mesenchymal Stem Cell Transplantation - adverse effects; Mesenchymal Stem Cells; Patients; Response rates; Transforming Growth Factor beta; Umbilical Cord; China; Autoimmunity; B-Lymphocytes; Lupus Erythematosus, Systemic

BackgroundReports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of umbilical cord derived MSCs in patients refractory to 6 months of immunosuppressive therapy.MethodsS...